NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 66.5% and is now trading at $21.76. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics Inc (NASDAQ:HARP) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.11. The business had revenue of $3.30 million for the quarter, compared to analyst estimates of $7.58 million. Harpoon Therapeutics had a negative net margin of 681.41% and a negative return on equity of 53.62%. View Harpoon Therapeutics' earnings history.

5 brokerages have issued 1-year target prices for Harpoon Therapeutics' shares. Their forecasts range from $26.00 to $35.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View analysts' price targets for Harpoon Therapeutics.

News headlines about HARP stock have trended somewhat negative on Saturday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutHarpoon Therapeutics.

Harpoon Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 245,300 shares, a decline of 21.9% from the April 30th total of 314,100 shares. Based on an average daily volume of 80,800 shares, the short-interest ratio is presently 3.0 days. Currently, 1.7% of the company's shares are sold short. View Harpoon Therapeutics' Current Options Chain.

Some companies that are related to Harpoon Therapeutics include Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Cortexyme (CRTX), Translate Bio (TBIO), NanoString Technologies (NSTG) and Proteon Therapeutics (PRTO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Tcr2 Therapeutics (TCRR), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA) and Stoke Therapeutics (STOK).

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.21%), Soleus Capital Management L.P. (1.88%), DAFNA Capital Management LLC (0.59%), Nuveen Asset Management LLC (0.58%), State Street Corp (0.58%) and Bailard Inc. (0.46%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View institutional ownership trends for Harpoon Therapeutics.

HARP stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and Deutsche Bank AG. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle. View insider buying and selling activity for Harpoon Therapeutics.

HARP stock was acquired by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., BlackRock Inc., DAFNA Capital Management LLC, Nuveen Asset Management LLC, Bailard Inc., Squarepoint Ops LLC, State Street Corp, and Geode Capital Management LLC. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin. View insider buying and selling activity for Harpoon Therapeutics.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HARP stock can currently be purchased for approximately $21.76.

Harpoon Therapeutics has a market capitalization of $544 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]